Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Thiogenesis Therapeutics Corp ( (TSE:TTI) ) is now available.
Thiogenesis Therapeutics has initiated an investigator-initiated study collaboration with leading cystinosis expert Dr. Larry Greenbaum at Emory University and Children’s Healthcare of Atlanta to evaluate its lead candidate TTI-0102 in nephropathic cystinosis patients, focusing on once-daily dosing, tolerability, and white blood cell cystine control to support dose optimization and inform a planned Phase 3 pivotal program. The company is also advancing a newly patented salt formulation of TTI-0102, scaling up manufacturing and conducting stability testing in parallel with finalizing an IND for cystinosis, with the aim of launching a Phase 3 non-inferiority trial against an approved cysteamine therapy under the FDA’s 505(b)(2) pathway, potentially offering a more convenient, better-tolerated treatment that could enhance adherence and quality of life for patients while providing a relatively efficient regulatory route to registration.
More about Thiogenesis Therapeutics Corp
Thiogenesis Therapeutics Corp. is a clinical-stage biotechnology company focused on developing next-generation sulfur-based prodrugs for rare pediatric diseases. Its lead candidate, TTI-0102, is a cysteamine-based disulfide prodrug designed to improve on existing cysteamine therapies for conditions such as nephropathic cystinosis by enabling sustained exposure, once-daily oral dosing, improved tolerability, and potential dual benefits in cystine depletion and intracellular antioxidant pathways.
Average Trading Volume: 23,849
Technical Sentiment Signal: Sell
Current Market Cap: C$31.88M
See more data about TTI stock on TipRanks’ Stock Analysis page.